<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01338389</url>
  </required_header>
  <id_info>
    <org_study_id>11-PP-04</org_study_id>
    <nct_id>NCT01338389</nct_id>
  </id_info>
  <brief_title>Influence of Oral Treatment With Citicoline for the Prevention of Radiation Optic Neuropathy in Patients Treated for Uveal Melanomas With Proton Beam Therapy</brief_title>
  <official_title>Influence of Oral Treatment With Citicoline for the Prevention of Radiation Optic Neuropathy in Patients Treated for Uveal Melanomas With Proton Beam Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DENSMORE pharmaceuticals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Proton beam irradiation is the treatment of choice for uveal melanomas. It has favorable
      results in causing tumor regression while preserving the eye. Optic neuropathy has emerged
      consistently as an irreversible cause of visual loss in proton beam irradiated eyes. No
      neuroprotective strategies are available at present.

      Citicoline is a choline agent precursor available as a dietary supplement. Citicoline
      conferred acute neuroprotection and enhanced neuroplasticity in experimental stroke models.
      In ophthalmology, citicoline has demonstrated a significant action in improving retinal and
      cortical responses in patients with optic nerve diseases (glaucoma, ischemic optic
      neuropathy). Citicoline also exhibits a very low toxicity profile in humans.

      The purpose of the study is to demonstrate whether daily oral administration of citicoline in
      patients treated for uveal melanomas with proton beam therapy, prevents or delays the
      occurrence of radiation optic neuropathy. Changes in visual acuity, Pattern ERG and visual
      evoked potentials are measured. The tolerability/safety of the product is also evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 25, 2012</start_date>
  <completion_date type="Anticipated">June 29, 2023</completion_date>
  <primary_completion_date type="Actual">June 29, 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence and delay of occurrence of radiation optic neuropathy</measure>
    <time_frame>Every 6 months</time_frame>
    <description>Occurrence and delay of occurrence of radiation optic neuropathy in patients treated for uveal melanomas with proton beam therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual function assessment</measure>
    <time_frame>Every 6 months</time_frame>
    <description>Best corrected visual acuity (ETDRS) ; Pattern ERG ; Visual Evoked potentials; adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Uveal Melanoma</condition>
  <arm_group>
    <arm_group_label>CITICOLINE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily oral administration of 800 mg citicoline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily oral administration of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>CITICOLINE</intervention_name>
    <description>Oral administration of CITICOLINE:
Form: Powder for solution Dosage: 800mg per day duration: 5 years</description>
    <arm_group_label>CITICOLINE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>PLACEBO</intervention_name>
    <description>Oral administration of placebo:
Form: Powder for solution duration: 5 years</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  over 18 years old

          -  uveal melanoma with posterior marge located at less than 3 mm of optic papilla

          -  uveal melanoma treated with proton beam therapy with irradiation of optic head nerve

          -  visual acuity before proton beam therapy over 30 letters (with ETDRS test)

        Exclusion Criteria:

          -  antecedent of acute glaucoma with angle enclosure

          -  antecedent of chronical glaucoma with angle aperture

          -  antecedent of optic neuropathy optique of congenital, ischemic, inflammatory or other
             origins

          -  antecedent of neovascular glaucoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>St√©phanie BAILLIF-GOSTOLI, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ophtalmology department, Nice University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de NICE</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophtalmology Departement, St Roch Hopital, Nice University Hospital</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2011</study_first_submitted>
  <study_first_submitted_qc>April 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2011</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Uveal Neoplasms</mesh_term>
    <mesh_term>Optic Nerve Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytidine Diphosphate Choline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

